Combined cisplatin with metformin [285], combined inhibition of SRC, PI3K, and MEK1/2 [286], HSP90 inhibition [239], FAK inhibition [287], hexosamine biosynthesis pathway inhibition [288], and a mitochondrial inhibitor phenformin [289] have been found effective in KRAS/LKB1 co-mutated lung cancer models. Here, KRAS is linked to lung carcinoma.